| Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia DJ Kuter, M Efraim, J Mayer, M Trněný, V McDonald, R Bird, ... New England Journal of Medicine 386 (15), 1421-1431, 2022 | 109 | 2022 |
| Phase I/II, open-label, adaptive study of oral bruton tyrosine kinase inhibitor PRN1008 in patients with relapsed/refractory primary or secondary immune thrombocytopenia DJ Kuter, RV Boccia, EJ Lee, M Efraim, N Tzvetkov, J Mayer, M Trněný, ... Blood 134, 87, 2019 | 17 | 2019 |
| Oral rilzabrutinib, a Bruton tyrosine kinase inhibitor, showed clinically active and durable platelet responses and was well-tolerated in patients with heavily pretreated … DJ Kuter, M Efraim, J Mayer, V McDonald, RJ Bird, T Regenbogen, ... Blood 136, 13-14, 2020 | 15 | 2020 |
| Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia DJ Kuter, J Mayer, M Efraim, LH Bogdanov, R Baker, Z Kaplan, M Garg, ... Blood advances 8 (7), 1715-1724, 2024 | 5 | 2024 |
| Updated phase I/II safety and efficacy results for oral bruton tyrosine kinase inhibitor rilzabrutinib in patients with relapsed/refractory immune thrombocytopenia DJ Kuter, N Tzvetkov, M Efraim, Z Kaplan, J Mayer, P Choi, AJG Jansen, ... Blood 138, 14, 2021 | 5 | 2021 |
| Phase i/ii ongoing study of rilzabrutinib, an oral bruton tyrosine kinase inhibitor, in immune thrombocytopenia: EXTENDED follow-up and long-term analyses with optimal dose. DJ Kuter, N Tzvetkov, M Efraim, Z Kaplan, J Mayer, P Choi, AJG Jansen, ... Research and Practice in Thrombosis and Haemostasis, 2021 | 4 | 2021 |
| Detection of EBV DNA in non-Hodgkin lymphoma patients in Bulgaria T Kostadinova, LI Ivanova, TT Todorova, Z Stoykova, D Staykov, M Efraim, ... Indian Journal of Hematology and Blood Transfusion 35, 465-470, 2019 | 3 | 2019 |
| One-minute time interval estimation as a novel potent indicator of emotional concerns in cancer patients prior to starting chemotherapy IS Donev, DS Stoyanov, TV Panayotova, MS Ivanova, YK Kashlov, ... Current Psychology 40, 3997-4003, 2021 | 2 | 2021 |
| Efficacy of Inotuzumab Ozogamicin plus Ponatinib Followed by Allogeneic Stem Cell Transplantation in a Patient with Relapsed Philadelphia Chromosome‐Positive Acute … I Micheva, V Gerov, S Dimitrova, M Efraim Case Reports in Hematology 2021 (1), 1717506, 2021 | 2 | 2021 |
| Outcome after azacitidine treatment in patients with high-risk myelodysplastic syndrome and acute myeloid leukemia in the Clinic of Hematology at St. Marina University Hospital … I Micheva, V Gerov, S Dimitrova, M Efraim, L Gercheva Scripta Scientifica Medica 50 (1), 31-35, 2018 | 2 | 2018 |
| OC 65.1 Long-Term Efficacy and Safety with Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Immune Thrombocytopenia D Kuter, M Efraim, Z Kaplan, J Mayer, P Choi, GAJ Jansen, V McDonald, ... Research and Practice in Thrombosis and Haemostasis 7, 2023 | 1 | 2023 |
| Long-Term Efficacy and Safety with Oral Bruton Tyrosine Kinase Inhibitor Rilzabrutinib in Patients with Immune Thrombocytopenia. D Kuter, T Gernsheimer, W Ghanima, U Khan, B Ward, A Daak, N Cooper Research and Practice in Thrombosis and Haemostasis, 2024 | | 2024 |
| Myasthenia gravis as an unusual non-hematological autoimmune manifestation of a relapsed chronic lymphocytic leukemia–clinical case and review of literature S Dimitrova, M Efraim, I Micheva Eur Rev Med Pharmacol Sci 27 (2), 649-652, 2023 | | 2023 |
| S291: PHASE I/II STUDY OF RILZABRUTINIB, AN ORAL BRUTON TYROSINE KINASE INHIBITOR, IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA: LONG-TERM FOLLOW-UP DJ Kuter, M Efraim, Z Kaplan, J Mayer, P Choi, AG Jansen, V McDonald, ... HemaSphere 6, 192-193, 2022 | | 2022 |
| The role of MDS-CI in the prognostic assessment of patients with myelodysplastic syndrome M Efraim, I Micheva Izvestia Journal of the Union of Scientists-Varna. Medicine and Ecology …, 2021 | | 2021 |
| Phase I/II updated safety and efficacy results of oral bruton tyrosine kinase (BTK) inhibitor rilzabrutinib in relapsed/refractory immune thrombocytopenia (ITP). DJ Kuter, N Tzvetkov, M Efraim, Z Kaplan, J Mayer, P Choi, A Jansen, ... Lippincott Williams and Wilkins, 2021 | | 2021 |
| PROGNOSTIC SIGNIFICANCE OF COMORBIDITIES AND FRAILTY IN RISK STRATIFICATION OF PATIENTS WITH MYELODYSPLASTIC SYNDROME M Efraim, I Micheva LEUKEMIA RESEARCH 108, S41-S41, 2021 | | 2021 |
| Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: PROGNOSTIC SIGNIFICANCE OF COMORBIDITIES AND FRAILTY IN RISK STRATIFICATION OF PATIENTS WITH … M Efraim, I Micheva Leukemia Research 108, 106681.4, 2021 | | 2021 |
| Sociodemographic Characteristics Of Survival In Patients With Myelodysplastic Syndrome M Efraim, I Micheva Varna Medical Forum 10 (2), 507-510, 2021 | | 2021 |
| Case Report Efficacy of Inotuzumab Ozogamicin plus Ponatinib Followed by Allogeneic Stem Cell Transplantation in a Patient with Relapsed Philadelphia Chromosome-Positive Acute … I Micheva, V Gerov, S Dimitrova, M Efraim | | 2021 |
Ilina Micheva, Илина Мичева, Ιλινα Μ...Medical University- Varna在 mu-varna.bg 的电子邮件经过验证
Ilina Micheva, Илина Мичева, Ιλινα Μ...Medical University- Varna在 mu-varna.bg 的电子邮件经过验证
Stela DimitrovaУМБАЛ "Св. Марина" Варна, Медицински университет - Варна